Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 3/20 | 0.35 |
| ▸ | FPR1 | P21462 | 3/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.34 |
| ▸ | HTR6 | P50406 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700741 | 0.95 | PTGDR2 (0.34) | COMTFPR1PTGDR2HTR6KCNH2 | |
| SCHEMBL476413 | 0.90 | ABCC9 (0.35) | FPR1HTR6 | |
| SCHEMBL3697998 | 0.89 | P2RX7 (0.35) | PTGDR2MMP2MMP9MMP8MMP13 | |
| SCHEMBL476336 | 0.88 | HTR6 (0.31) | FPR1HTR6 | |
| SCHEMBL476393 | 0.86 | APLNR (0.34) | FPR1 | |
| SCHEMBL3699026 | 0.83 | PTGDR2 (0.35) | FPR1PTGDR2HTR6KCNH2 | |
| SCHEMBL3697760 | 0.83 | NR1I2 (0.35) | PTGDR2P2RX7 | |
| SCHEMBL3698417 | 0.82 | PLCG1 (0.33) | PTGDR2HTR6KCNH2P2RX7 | |
| SCHEMBL3697138 | 0.81 | SLC16A3 (0.34) | KCNH2 | |
| SCHEMBL3693159 | 0.81 | FPR1 (0.42) | FPR1PTGDR2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895588-B2 | Pyrazole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20120095057-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2412713-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095057-A1 | PYRAZOLE COMPOUND | CEL, HRH2, GIPR | COMT 4484/4885FPR1 433/4885PTGDR2 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.